GlaxoSmithKline (GSK) - Get Report announced Tuesday after the market closed that it is buying Sirtris Pharmaceuticals (SIRT) for $720 million, or $22.50 a share. $376M. Find the latest Genocea Biosciences, Inc. (GNCA) stock quote, history, news and other vital information to help you with your stock trading and investing. //-->. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. GBP11.33) per share followed by a second step merger in which any untendered Sirtris shares would be acquired at the same price per share. [6] Studies published in 2009 and early 2010 by scientists from Amgen and Pfizer cast doubt on whether SIRT1 was directly activated by resveratrol and showed that the apparent activity was actually due to a fluorescent reagent used in the experiments. Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. The stock market hasn't been kind to Sirtris, which was trading at $12, down 45% from its 52-week high. Action Alerts PLUS is a registered trademark of TheStreet, Inc. Their stock opened with $10.00 in its May 23, 2007 IPO. Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23. The proposed acquisition of Sirtris Pharmaceuticals (SIRT) is essentially aneffort to bolster GlaxoSmithKline's (NYSE:GSK)s pipeline in the Type 2 diabetes treatmentarea. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23. The company also has discovered new chemical entities that are significantly more potent activators of SIRT1 and should enter the clinic this year, according to some analysts. The $22.50 per Sirtris share that GSK paid as part of the deal represented a nearly 85 percent premium to Sirtris’ stock price at the time the deal was announced. Under the agreement, a subsidiary of GSK will commence a cash tender offer to purchase all of the outstanding shares of Sirtris, at USD22.50 (or approx. GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share. SIRTRIS PHARMA INC. Weekly Stock Prices Chart. Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. Sirtris Pharmaceuticals (NASDAQ:SIRT) ... as seen by today's 15% drop in the stock price, the stock still looks a little overpriced for a company with one drug in … TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. document.write("
Click here to add this page to your favorites"); Latest Deal Amount. Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … © 2021 TheStreet, Inc. All rights reserved. Sirtris Pharmaceuticals Files for $60 Million IPO Published: Mar 01, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. if ((navigator.appVersion.indexOf("MSIE") > 0) && (parseInt(navigator.appVersion) >= 4)) { weekly.TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. Description. Sirtris Pharmaceuticals Inc. filed with regulators on Thursday to raise up to $60 million in an initial public offering of common stock. Glaxo's shares edged up 9 cents, or 0.2% to $43.82 in recent post-market trading. [Updated 2:25 pm ET, 3/13/13] GlaxoSmithKline is closing down Cambridge, MA-based Sirtris Pharmaceuticals, almost five years after it paid $720 million to … M&A. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. Sirtris Pharmaceuticals, Inc. SEC Form 4 Filed December 4, 2007: Statement of changes in beneficial ... Last Updated December 17, 2020 at 7:56 AM EST Back to Sirtris Pharmaceuticals, Inc. Markets Data Center: Biggest Price Gainers. Type 2 Diabetes (T2D) has reached epidemic proportions in the United States. Sirtris Pharmaceuticals is registered under the ticker NASDAQ:SIRT . News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. The startup’s activity is discovering and developing proprietary, orally available, small molecule drugs with the potential to treat metabolic diseases such as Type 2 Diabetes and such of aging by modulating sirtuins, a recently discovered class of enzymes. They are buying Sirtris Pharmaceuticals for $720M in cash, or $22.50/share. Sirtris founder and CEO Christoph Westphal will remain head of the unit once the cash sale of about $22.50 per share closes later this year. Sirtris Pharmaceuticals™ (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. As part of a potential partnership with GlaxoSmithKline, Sirtris suggested the British pharmaceuticals giant buy a stake for $25 per share, nearly double Sirtris's stock price at the time. Biopharmaceutical company Sirtris Pharmaceuticals Inc. said it would sell 5 million shares in its initial public offering at $9 to $11 apiece. Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.